An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia

References

• Cancer net; 2019 [cited July 21, 2019]. Available from https://www.cancer.net/cancer-types/leukemia-chronic-myeloid-cml/statistics.
   Google Scholar
• Bower H, Bjorkholm M, Dickman PW, et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851–2857.
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251–2259.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260–2270.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36(3):231–237.
   PubMed Web of Science ®Google Scholar
• Chen K-K, Du T-F, Wu K-S, et al. First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis. Cancer Manag Res. 2018;10:3891–3910.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30(28):3486–3492.
   PubMed Web of Science ®Google Scholar
• Fachi MM, Tonin FS, Leonart LP, et al. Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: a systematic review and network meta-analysis. Eur J Cancer. 2018;104:9–20.
   PubMed Web of Science ®Google Scholar
• A multicenter phase 3 randomized, open-label study of bosutinib versus imatinib in adult patients with newly diagnosed chronic phase chronic myelogenous leukemia (BFORE) – full clinical study report. Avillion Development 1 Limited. 2016.
   Google Scholar
• Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12(9):841–851.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119(5):1123–1129.
   Google Scholar
• Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940–947.
   PubMed Web of Science ®Google Scholar
• Ishak KJ, Proskorovsky I, Benedict A. Simulation and matching-based approaches for indirect comparison of treatments. Pharmacoeconomics. 2015;33(6):537–549.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Summary of product characteristics: Tasigna (nilotinib); 2019. Available from https://www.ema.europa.eu/documents/product-information/tasigna-epar-product-information_en.pdf.
   Google Scholar
• Signorovitch JE, Betts KA, Reichmann WM, et al. One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison. Curr Med Res Opin. 2015;31(2):315–322.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Summary of product characteristics: Sprycel (dasatinib); 2016. Available from: https://www.ema.europa.eu/documents/product-information/sprycel-epar-product-information_en.pdf.
   Google Scholar
• ClinicalTrial.gov website; identifier numbers: NCT00481247; CA 180-056; February 2017 [cited 2020 Feb 19]. https://clinicaltrials.gov/ct2/show/results/NCT00481247?view=results.
   Google Scholar
• Bendel RB, Afifi AA. Comparison of stopping rules in forward regressions. J Am Stat Assoc. 1977;72:46–53.
   Web of Science ®Google Scholar
• Mickey J, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol. 1989;129(1):125–137.
   PubMed Web of Science ®Google Scholar
• Phillippo D, Dias S, Palmer S, et al. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE; 2016.
   Google Scholar
• Phillippo DM, Ades AE, Dias S, et al. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200–211.
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Wu EQ, Betts KA, et al. Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials. Curr Med Res Opin. 2011; 27(6):1263–1271.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Muresan B, Mamolo C, et al. Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia. Curr Med Res Opin. 2019;35(9):1615–1622.
   PubMed Web of Science ®Google Scholar
• Pfirrmann M, Hochhaus A, Lauseker M, et al. Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. Leukemia. 2011;25(9):1433–1438.
   PubMed Web of Science ®Google Scholar
• NCCN clinical practice guidelines in oncology (NCCN guidelines). Chronic myeloid leukemia, version 1.2019 – August 1, 2018.
   Google Scholar
• Breccia M, Alimena G. The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era. Crit Rev Oncol Hematol. 2011;79(2):135–143.
   PubMed Web of Science ®Google Scholar
• Bonifazi F, De Vivo A, Rosti G, et al. Testing Sokal’s and the new prognostic score for chronic myeloid leukaemia treated with α-interferon. Br J Haematol. 2000;111(2):587–595.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984.
   PubMed Web of Science ®Google Scholar
• Protocol for: Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251–2259. DOI:https://doi.org/10.1056/NEJMoa0912614
   PubMed Web of Science ®Google Scholar
• Protocol for: Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260–2270. DOI:https://doi.org/10.1056/NEJMoa1002315
   PubMed Web of Science ®Google Scholar
• Protocol for: Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36(3). DOI:https://doi.org/10.1200/JCO.2017.74.7162
   Google Scholar